Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Treatment Outcomes and Prognostic Factors of Metastasis-Directed Radiation Therapy for Oligometastatic Endometrial Cancer.Advances in radiation oncology · 2026Article
- Review
- Phosphorylation of RBM39 by CDK13 stabilizes RAD50 mRNA to drive cisplatin resistance in endometrial cancer.The Journal of biological chemistry · 2026Article
- Proton beam therapy as an effective treatment option for recurrent endometrial cancer.Gynecologic oncology reports · 2026Article
- High levels of P2RX5 expression predicts a poor prognosis and promotes tumor progression in endometrial cancer.International journal of clinical and experimental pathology · 2026Article
- Clinicopathological and preoperative biomarkers associated with recurrence after primary surgical treatment for endometrial cancer.Frontiers in oncology · 2026Article
- Risk Factors for Colostomy after Chemoradiotherapy in Patients with Squamous Cell Carcinoma of the Anus: A Nationwide, Multicenter Analysis in Japan.Journal of the anus, rectum and colon · 2026Article
- COX7A1-mediated mitochondrial dysfunction can induce ferroptosis in endometrial cancer cells.PloS one · 2026Article
- Cancer of the corpus uteri: A 2025 update.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Review
- Synergistic effect of MDM2 inhibitors and radiotherapy in endometrial cancer.NPJ precision oncology · 2025Article
- Recent Advances in Combination Therapy of YAP Inhibitors with Physical Anti-Cancer Strategies.Biomolecules · 2025Review
- The Impact of Salvage Radiotherapy in Recurrent Endometrial Cancer: A Review Focusing on Early-Stage, Endometrial Cancer Locoregional Relapses.Life (Basel, Switzerland) · 2025Review
- Translating biological insights into improved management of endometrial cancer.Nature reviews. Clinical oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 19 institutions in 1 country.
Funding
Abstract
purposePelvic recurrence is a frequent pattern of relapse for women with endometrial cancer. A randomized trial compared progression-free survival (PFS) after treatment with radiation therapy alone as compared with concurrent chemotherapy. MATERIALS AND
methodsBetween February 2008 and August 2020, 165 patients were randomly assigned 1:1 to receive either radiation treatment alone or a combination of chemotherapy and radiation treatment. The primary objective of this study was to determine whether chemoradiation therapy was more effective than radiation therapy alone at improving PFS.
resultsThe majority of patients had low-grade (1 or 2) endometrioid histology (82%) and recurrences confined to the vagina (86%). External beam with either the three-dimensional or intensity modulated radiation treatment technique was followed by a boost delivered with brachytherapy or external beam. Patients randomly assigned to receive chemotherapy were treated with once weekly cisplatin (40 mg/m
conclusionExcellent outcomes can be achieved for women with localized recurrences of endometrial cancer when treated with radiation therapy. The addition of chemotherapy does not improve PFS for patients treated with definitive radiation therapy for recurrent endometrial cancer and increases acute toxicity. Patients with low-grade and vaginal recurrences who constituted the majority of those enrolled are best treated with radiation therapy alone.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.